VINORELBINE TARTRATE Drug Patent Profile
✉ Email this page to a colleague
When do Vinorelbine Tartrate patents expire, and when can generic versions of Vinorelbine Tartrate launch?
Vinorelbine Tartrate is a drug marketed by Actavis Totowa, Dr Reddys, Ebewe Pharma, Fresenius Kabi Usa, Hikma, Hospira, Jiangsu Hansoh Pharm, Mylan Labs Ltd, Novast Labs, and Teva Pharms Usa. and is included in eleven NDAs.
The generic ingredient in VINORELBINE TARTRATE is vinorelbine tartrate. There are fifteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the vinorelbine tartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vinorelbine Tartrate
A generic version of VINORELBINE TARTRATE was approved as vinorelbine tartrate by HIKMA on June 10th, 2003.
Summary for VINORELBINE TARTRATE
US Patents: | 0 |
Applicants: | 10 |
NDAs: | 11 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 75 |
Clinical Trials: | 80 |
Patent Applications: | 7,215 |
Formulation / Manufacturing: | see details |
DailyMed Link: | VINORELBINE TARTRATE at DailyMed |
Recent Clinical Trials for VINORELBINE TARTRATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 3 |
Qilu Pharmaceutical Co., Ltd. | Phase 3 |
Zhiyong Yu | Phase 2 |
Pharmacology for VINORELBINE TARTRATE
Drug Class | Vinca Alkaloid |